^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CTLA4 inhibitor

    Related drugs:
    1d
    An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Peking Union Medical College Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Qibeian (iparomlimab/tuvonralimab)
    1d
    Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Kaitanni (cadonilimab)
    2d
    Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden • IO biomarker
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MSH6 (MutS homolog 6)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (clinicaltrials.gov)
    P1/2, N=129, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • pumitamig (BNT327)
    2d
    Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer (clinicaltrials.gov)
    P2, N=38, Recruiting, University of Chicago | Suspended --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • volrustomig (MEDI5752)
    2d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) (clinicaltrials.gov)
    P1/2, N=234, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • pumitamig (BNT327)
    2d
    NRG-BN007: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (clinicaltrials.gov)
    P2/3, N=159, Completed, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH1 R132
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • ABP 206 (nivolumab biosimilar)
    2d
    GlitIpNi: A phase IB clinical trial on neoadjuvant and intraoperative intracranial nadministration of triple immune checkpoint blockade plus myeloid dendritic ncells in patients with recurrent high-grade glioma (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Universitair Ziekenhuis Brussel | Phase classification: P1/2 --> P1
    Phase classification • Checkpoint inhibition
    |
    IDH wild-type
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw)
    2d
    Safe Stop ipi-nivo (2024-516938-34-00`2022-002673-28)
    P2/3, N=80, Recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    3d
    A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=422, Not yet recruiting, Akeso
    New P3 trial
    |
    capecitabine • oxaliplatin • Kaitanni (cadonilimab)
    3d
    Rapidly Progressive Overlap of Immune Checkpoint Inhibitor-Induced Myositis and Myasthenia Gravis: Diagnostic and Therapeutic Challenges. (PubMed, Cureus)
    We report a fulminant case of overlap syndrome involving ICI-induced myositis and myasthenia gravis in a 72-year-old man receiving ipilimumab-nivolumab for hepatocellular carcinoma and recurrent renal cell carcinoma...Despite prompt intensive care admission and treatment with high-dose intravenous methylprednisolone and intravenous immunoglobulin, only partial clinical improvement was achieved. The subsequent development of aspiration pneumonia led to acute respiratory and hepatic failure, culminating in death. This case underscores the aggressive clinical trajectory and high mortality of ICI-related neuromuscular overlap syndromes, highlighting the critical need for early recognition, rapid immunosuppression, and multidisciplinary management.
    Journal • Checkpoint inhibition
    |
    MB (Myoglobin)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • methylprednisolone sodium succinate
    3d
    Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study. (PubMed, Front Oncol)
    This study confirms the promising efficacy and acceptable safety profile of AK104 combination therapy in patients with driver gene-negative advanced NSCLC. These findings collectively support the need for further large-scale prospective studies to validate its clinical utility.
    Retrospective data • Journal • Real-world evidence
    |
    PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • PD-L1 negative
    |
    Kaitanni (cadonilimab)